EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hexokinase 2 nonmetabolic function‐mediated phosphorylation of IκBα enhances pancreatic ductal adenocarcinoma progression

Yingying Tong, Xin Liu, Lihui Wu, Yaoxian Xiang, Jing Wang, Yurong Cheng, Chan Zhang, Baojuan Han, Li Wang, Dong Yan iD

Cancer Science · 2024

DOI: 10.1111/cas.16204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Yingying Tong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Hexokinase, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, NF-KappaB Inhibitor alpha. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Municipal Natural Science Foundation, R&D Program of Beijing Municipal Education Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant signaling in tumor cells induces nonmetabolic functions of some metabolic enzymes in many cellular activities. As a key glycolytic enzyme, the nonmetabolic function of hexokinase 2 (HK2) plays a role in tumor immune evasion. However, whether HK2, dependent of its nonmetabolic activity, plays a role in human pancreatic ductal adenocarcinoma (PDAC) tumorigenesis remains unclear. Here, we demonstrated that HK2 acts as a protein kinase and phosphorylates IκBα at T291 in PDAC cells, activating NF‐κB, which enters the nucleus and promotes the expression of downstream targets under hypoxia. HK2 nonmetabolic activity‐promoted activation of NF‐κB promotes the proliferation, migration, and invasion of PDAC cells. These findings provide new insights into the multifaceted roles of HK2 in tumor development and underscore the potential of targeting HK2 protein kinase activity for PDAC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HexokinaseCarcinoma, Pancreatic DuctalPancreatic NeoplasmsNF-KappaB Inhibitor alphaNF-kappa BCell ProliferationHumansPhosphorylationCell Line, TumorDisease ProgressionAnimalsCell MovementMiceSignal TransductionFemaleMale

Stichwörter der Autor:innen

HK2IκBαnonmetabolic activitypancreatic ductal adenocarcinomatumor progression

Substanzen

HexokinaseHK2 protein, humanNF-KappaB Inhibitor alphaNF-kappa B

Autor:innen und Institutionen

  • Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
  • Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: Dong Yan

Förderung

  • Beijing Municipal Natural Science Foundation
  • R&D Program of Beijing Municipal Education Commission
  • National Natural Science Foundation of China

Zitieren

APA

Tong, Y., Liu, X., Wu, L., Xiang, Y., Wang, J., Cheng, Y., Zhang, C., Han, B., Wang, L., & Yan, D. (2024). Hexokinase 2 nonmetabolic function‐mediated phosphorylation of IκBα enhances pancreatic ductal adenocarcinoma progression. Cancer Science. https://doi.org/10.1111/cas.16204

Vancouver

Tong Y, Liu X, Wu L, Xiang Y, Wang J, Cheng Y, et al. Hexokinase 2 nonmetabolic function‐mediated phosphorylation of IκBα enhances pancreatic ductal adenocarcinoma progression. Cancer Science. 2024. doi:10.1111/cas.16204

BibTeX
@article{Tong2024,
  author = {Tong, Yingying and Liu, Xin and Wu, Lihui and Xiang, Yaoxian and Wang, Jing and Cheng, Yurong and Zhang, Chan and Han, Baojuan and Wang, Li and Yan, Dong},
  title = {Hexokinase 2 nonmetabolic function‐mediated phosphorylation of IκBα enhances pancreatic ductal adenocarcinoma progression},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16204}
}
Kostenlos starten →